The British Business Bank (BBB) has reinforced its role as a key driver of the UK’s venture ecosystem. As the government’s economic development arm, established over a decade ago, the BBB continues to channel significant funds into high-potential sectors, aiming to spur growth in smaller enterprises and attract private investment. These latest commitments highlight a focus on deep technology, energy platforms, and life sciences, aligning with national priorities like the Modern Industrial Strategy.
One major initiative involves a substantial £50 million anchor investment in IQ Capital’s Fund V.
This Cambridge and London-based venture firm, with roots dating back to 2005, specializes in nurturing nascent deep tech startups.
The fund targets five core domains: artificial intelligence and automation, semiconductors and computing, health and biotechnology, advanced engineering and energy solutions, plus security and resilience technologies.
By supporting entrepreneurs from initial ideation to expansion phases, IQ Capital has already aided over 250 innovators, leading to acquisitions by giants such as Apple, Google, and Siemens.
This partnership marks an extension of a 20-year collaboration with the BBB, which has previously co-invested in successes like Thought Machine and Paragraf.
Officials at the BBB praised IQ Capital’s proven ability to spot and scale early opportunities, noting it exemplifies the long-term benefits of such backing.
A representative from IQ Capital echoed this, emphasizing how the support enables the creation of enterprises from UK talent.
Shifting to direct investments, the BBB has pledged £25 million to Kraken Technologies, marking its most significant single-company outlay yet.
Emerging from a $1 billion separation from Octopus Energy Group, Kraken operates as an independent AI-driven platform for utilities, managing over 70 million customer accounts globally.
Its expansion—quadrupling contracted revenues to more than $500 million in just three years—stems from handling massive data volumes daily.
This move fits into the BBB’s updated approach post-2025 reforms, which empower larger co-investments in scaling firms.
By partnering with Octopus Ventures, the BBB aims to spotlight and bolster UK scale-ups in critical areas like sustainable energy.
Investment leaders at the BBB described this as a bolder step to champion globally competitive tech, directly supporting the industrial agenda.
Complementing these efforts, the BBB has also committed another £50 million as a cornerstone to Epidarex Capital’s forthcoming fund.
Building on a 2020 investment that helped raise £102 million for life sciences ventures, this Edinburgh-headquartered firm focuses on seed and early-stage funding for breakthroughs in oncology, inflammation, cardiometabolic conditions, and neuroscience.
Epidarex collaborates closely with UK universities to commercialize research, incubating companies that develop novel therapies and devices.
The BBB views this as vital for sustaining the UK’s research pipeline, having already funneled over £500 million into similar funds.
Executives highlighted the need for specialized investors to turn scientific ideas into viable businesses, while Epidarex’s founders expressed enthusiasm for advancing patient-focused innovations across the nation.
Collectively, these £125 million infusions underscore the BBB’s impact: since inception, it has facilitated £23 billion in financing for nearly 64,000 businesses.
By prioritizing cornerstone roles, the bank not only catalyzes fund closures but also mobilizes private capital, fostering a vibrant spinout environment where a quarter of recent university deals involve its support.
As the UK pushes for technological sovereignty and health advancements, these investments position the country as a hub for responsible innovation.
